eligibility_summary
Adults (≥18) with MM: DARA-based induction (≥3 cycles) with ≥PR and ASCT 90–150 d prior, MRD+ by clonoSEQ 10^-5 or M‑spike ≥0.5 g/dL/abnormal FLC, no post‑ASCT therapy/progression, ECOG ≤2, adequate marrow/liver/renal, ASCT tox ≤G1, contraception required. Exclude: active HIV/HCV, HBsAg+ or HBV DNA+, MRD–, recent MI/stroke or major surgery, can’t take prophylaxis/comply, serious cardiac or CNS disease, DARA intolerance, other active cancer, severe COPD/asthma (FEV1<50%), allergy to study drugs/IMiDs/monoclonals, pregnant/lactating, QTc>470, strong CYP3A4/P‑gp/BCRP inhibitors/inducers.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06107738 tests two maintenance agents post-ASCT in MRD-positive multiple myeloma: 1) Iberdomide (CC‑220), an oral cereblon E3 ligase modulator (CELMoD) immunomodulatory drug that binds CRBN to induce degradation of IKZF1/IKZF3 (Ikaros/Aiolos), downregulates IRF4/MYC, directly inhibits myeloma growth, and boosts T- and NK-cell activation and IL‑2 production. 2) Daratumumab/rHuPH20 (Darzalex Faspro), a subcutaneous anti‑CD38 IgG1 monoclonal antibody co-formulated with hyaluronidase to enable SC delivery, it targets CD38 on plasma cells, mediating ADCC, CDC, ADCP, and apoptosis, and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs). Cells/pathways targeted: CD38+ myeloma plasma cells, CRBN–IKZF1/3 axis, Fc/complement cytotoxic pathways, T/NK effector activation and tumor microenvironment immunosuppression.